Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2018 · 10-K
Revenue$270.70M$270.70M+39.7% vs Q4 2017 Net Income-$3.40M-$3.40MN/M vs Q4 2017 EPS Diluted-$0.07-$0.07N/M vs Q4 2017 Gross Profit$11,200,000−78.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$165,800,000N/M Free Cash Flowderived-$186,600,000N/M Margins · derivedGross margin4.1%−23.3 pt vs Q4 2017
Operating margin4.1%−23.3 pt vs Q4 2017
Net margin-1.3%−18.8 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 22, 2019 · 53 d after period end